-- Multiplex Test Panel for binx io(R) Point-of-Care Platform Positioned to 
Radically Reduce Time to Treatment, Expand Access to Care

binx health(TM), the pioneer in anywhere care today announced that its 
proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark 
approval. The new multiplex test works with the binx io platform, delivering a 
laboratory-quality result in about 30 minutes, creating a new model for 
"test-and-treat" care for two of the most prevalent Sexually Transmitted 
Infections (STIs) globally.

Logo - https://mma.prnewswire.com/media/880236/binx_Logo.jpg 

More than one million STIs are acquired worldwide every day with chlamydia and 
gonorrhea representing two of the most prevalent(1).  Recent data released by 
the European Centre for Disease Prevention and Control (ECDC) notes a striking 
rise in the cases of gonorrhea -- up 17% between 2016 and 2017 across the 
reporting EU/EEA countries, with some countries noting year-over-year spikes of 
more than 40%(2).  Similarly, in the United States, infection rates have risen 
an astonishing 67% since 2013, with rates continuing to be highest in the 20-24 
year-old age group.(3)

Today, the majority of CT/NG tests are sent to central laboratories, meaning 
there can be up to a seven day waiting period from first visit to treatment, 
during which time patients may continue to spread infection, with up to 40% of 
positive patients never returning for treatment(4). binx is positioned to 
radically change this paradigm, enabling patients and consumers to leave a 
retail pharmacy, primary care office, clinic, urgent care facility and any 
other brick-and-mortar location, with treatment in hand in a single visit 
(while the binx point-of-care platform is not yet available in the United 
States, the company recently completed its multi-center clinical study for 
submission to FDA for 510(k) clearance). The binx io platform is designed for 
ease-of-use, enabling non-laboratory-trained users to run a test with the same 
accuracy as a central lab test, making it ideal for use in a variety of 
approved medical and consumer settings. 

"Achieving a 30-minute diagnostic turnaround time for two of the most common 
STIs is a major public health breakthrough," explains Howard Heller, MD MPH, 
binx health's Chief Medical Officer. "Rapid results equal rapid, appropriate 
treatment.  This new panel enables a path to not just same day, but same visit 
testing and treatment, eliminating an immense barrier to care and cure."

"Modern healthcare delivery requires tools that meet consumers' needs where 
they live, work and shop," said Jeffrey Luber, binx health's Chief Executive 
Officer. "Doing this effectively means delivering fast, accurate, 
cost-effective solutions at brick-and-mortar locations, as well as 
physician-ordered, medical guideline-based testing online, that work to bring 
consumers from 'worry to well' in the locations most convenient for them. 
Through scientific rigor, guideline-based testing, and an 'anywhere' mindset 
that puts the consumer at the center of all we do, today we embark on a path to 
deliver omnichannel, high quality care in family health, starting with young 
people and STIs as our launching point." 

About binx health 
binx health(TM)  is the pioneer in anywhere care for consumers where they live, 
work and shop. We do this with (1) proprietary, rapid desktop PCR instruments 
for retail pharmacy, urgent care, primary care, health centers, and any other 
brick-and-mortar location where onsite, on demand testing and rapid results on 
par with central lab testing, are paramount, and (2) mobile solutions for 
at-home, physician-ordered testing that aim to bring consumers from 
"worry-to-well" in the palm of their hands. Starting with sexually-transmitted 
infections, we aim to reverse trends of rising infections among young people, 
and move into broader family health through the expansion of our point-of-care 
and at home offerings. binx health's investors include financial investors, 
Johnson & Johnson Innovation, Novartis Venture Fund, LSP Venture Capital, BB 
Biotech, RMI Investments and Technology Venture Partners and strategic 
investors, Consort Medical (whose wholly owned subsidiary Bespak are the makers 
of the company's low-cost, proprietary multi-plex cartridges) and China-based 
Wondfo Biotech.

1 WHO Key facts 28 Feb 2019
2 ECDC EUROPE ( 
https://c212.net/c/link/?t=0&l=en&o=2452460-1&h=398928791&u=https%3A%2F%2Fecdc.europa.eu%2Fen%2Fnews-events%2Fgonorrhoea-cases-rise-across-europe&a=EDCD+EUROPE 
) 
3 Division of STD Prevention ( 
https://c212.net/c/link/?t=0&l=en&o=2452460-1&h=1828350347&u=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Fdstdp&a=Division+of+STD+Prevention 
), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention ( 
https://c212.net/c/link/?t=0&l=en&o=2452460-1&h=1774383253&u=https%3A%2F%2Fwww.cdc.gov%2Fnchhstp&a=National+Center+for+HIV%2FAIDS%2C+Viral+Hepatitis%2C+STD%2C+and+TB+Prevention 
), Centers for Disease Control and Prevention ( 
https://c212.net/c/link/?t=0&l=en&o=2452460-1&h=3579834158&u=https%3A%2F%2Fwww.cdc.gov%2F&a=Centers+for+Disease+Control+and+Prevention 
) 
4 Gift, Thomas L. et al. Sex Tran Dis: April 1999 - Volume 26 - Issue 4 - p 
232--240 ( 
https://c212.net/c/link/?t=0&l=en&o=2452460-1&h=4095280197&u=https%3A%2F%2Fjournals.lww.com%2Fstdjournal%2Ftoc%2F1999%2F04000&a=April+1999+-+Volume+26+-+Issue+4+-+p+232%E2%80%93240 
)

SOURCE: binx health

CONTACT: Investor Contact, Marc Jones, +1 (603) 566-5353, 
marc.jones@mybinxhealth.com; Media Contact, Tony Labriola, +1 (978) 815-8640, 
tony@thinkinsideout.com